Skip to main
AAPG

AAPG Stock Forecast & Price Target

AAPG Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ascentage Pharma Group is a promising investment opportunity due to its strong pipeline of drugs in development such as ELVN-001, TERN-701, and APG-3288, which have shown positive results in clinical trials and have potential for global sales. Additionally, their partnership with Takeda and developing drugs with unique mechanisms of action for treating multiple sclerosis and cancer adds to their strength in the market. However, as a clinical-stage biopharmaceutical company, there are associated risks, and investors should carefully consider the company's financials and pipeline progression.

Bears say

Ascentage Pharma Group is a clinical-stage biotechnology company that is focused on developing and selling small-scale therapies for cancers, hepatitis B virus, and age-related diseases. While the company has a diverse pipeline and promising drug candidates in research, its current financials and market positioning in China do not align with the potential risks and challenges associated with its drug development and commercialization process. Additionally, the company's partnership with Takeda for the option rights to olverembatinib outside of Greater China and Russia could limit its potential market reach and growth opportunities.

AAPG has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ascentage Pharma Group International and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ascentage Pharma Group International (AAPG) Forecast

Analysts have given AAPG a Strong Buy based on their latest research and market trends.

According to 5 analysts, AAPG has a Strong Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ascentage Pharma Group International (AAPG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.